Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2021-11-12 00:00:00 ET · period of report 2021-11-12 · accession 0001735276-21-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-12 | 2021-11-12 | ALNY | MARAGANORE JOHN | CEO, Dir | S - Sale+OE | $171.52 | -34.0K | 214.8K | -14% | -$5.83M |
| D | 2021-11-12 | 2021-11-12 | ALNY | MARAGANORE JOHN | CEO, Dir | M - OptEx | $7.10 | +34.0K | 248.7K | +16% | +$241.2K |
| D | 2021-11-12 | 2021-11-12 | ALNY | MARAGANORE JOHN | CEO, Dir | M - OptEx | $0.00 | -34.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-12 | S | D | 10,365 | $170.36 | 238,378 | D | — | — | (F2) Sale prices ranged from $169.84 to $170.84. |
| 2 | Common | Common Stock | 2021-11-12 | S | D | 7,742 | $171.35 | 230,636 | D | — | — | (F3) Sale prices ranged from $170.85 to $171.82. |
| 3 | Common | Common Stock | 2021-11-12 | S | D | 14,518 | $172.22 | 216,118 | D | — | — | (F4) Sale prices ranged from $171.86 to $172.84. |
| 4 | Common | Common Stock | 2021-11-12 | S | D | 683 | $173.25 | 215,435 | D | — | — | (F5) Sale prices ranged from $172.90 to $173.34. |
| 5 | Common | Common Stock | 2021-11-12 | S | D | 670 | $174.34 | 214,765 | D | — | — | (F6) Sale prices ranged from $174.05 to $174.63. |
| 6 | Common | Common Stock | 2021-11-12 | M | A | 33,978 | $7.10 | 248,743 | D | — | — | |
| 7 | Derivative | Stock Option (right to buy) | 2021-11-12 | M | D | 33,978 | $0.00 | 0 | D | $7.10 · — to 2021-11-30 | 33,978 Common Stock | (F8) The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |